English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech Healthcare & Pharm
雅各臣建议分拆健倍苗苗(保健)有限公司于香港联合交易所有限公司主板独立上市
Jan 15, 2021 23:27 HKT
雅各臣建議分拆健倍苗苗(保健)有限公司於香港聯合交易所有限公司主板獨立上市
Jan 15, 2021 23:26 HKT
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
Jan 15, 2021 23:25 HKT
花旗首次覆蓋德琪醫藥(6996.HK),給予「買入」評級,目標價32.80港元
Jan 14, 2021 08:40 HKT
APOLLOMICS(冠科美博)UPROLESELAN(APL-106)注射液獲得國家CDE突破性療法認定
Jan 07, 2021 20:12 HKT
APOLLOMICS(冠科美博)UPROLESELAN(APL-106)注射液获得国家CDE突破性疗法认定
Jan 07, 2021 20:11 HKT
Mediwelcome: Bringing High-Quality Medical Service Genes, or an Internet Hospital Upstart?
Jan 07, 2021 01:00 HKT
Mediwelcome: Key Player in the Gold Track, is Forming a Head Leading Advantage
Jan 06, 2021 17:00 HKT
Mediwelcome: Reasonable valuation with HK listing on track for January 19
Jan 06, 2021 15:45 HKT
Azelis Acquires Majority Shareholding in MKVN Chemicals and Viet Chemi
Jan 06, 2021 15:20 HKT
Azelis significantly increases its market presence in Vietnam through the acquisition of a majority shareholding in MKVN Chemicals and Viet Chemi
Jan 05, 2021 14:35 HKT
Sự hiện diện của Azelis trên thị trường Việt Nam đã được củng cố sâu sắc sau thương vụ thu mua đa số cổ phần tại MKVN Chemicals và Viet Chemi
Jan 05, 2021 14:30 HKT
Epazz Developed Smart Contracts for HEMP IEO on the Asia Token Exchange
Dec 30, 2020 08:03 HKT
AIM ImmunoTech宣布其药物Ampligen的ME/CFS临床试验已开始接受COVID-19长期患者的注册
Dec 24, 2020 21:00 HKT
AIM ImmunoTech宣布其藥物Ampligen的ME/CFS臨床試驗已開始接受COVID-19長期患者的註冊
Dec 24, 2020 21:00 HKT
AIM ImmunoTech Announces that the ME/CFS Clinical Trial of its Drug Ampligen is Open for Enrollment to COVID-19 'Long Haulers'
Dec 24, 2020 21:00 HKT
Suntrap Life Technologies Discovers Natural anti-COVID-19 Compound
Dec 24, 2020 08:00 HKT
KIEYYUEL's disposable nitrile gloves - No.1 in the medical industry
Dec 24, 2020 06:00 HKT
China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level
Dec 21, 2020 19:00 HKT
賽生藥業與Y-mAbs就DANYELZA® (naxitamab-gqgk)和omburtamab兩款藥物達成大中華區產品授權合約
Dec 18, 2020 22:08 HKT
Next >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: